Skip to main content

Branded

  • Sunovion Pharmaceuticals announces availability of Aptiom

    MARLBOROUGH, Mass. — Sunovion Pharmaceuticals on Monday announced that Aptiom (eslicarbazepine acetate), a once-daily antiepileptic drug, is now available across the United States.

    The drug, which received approval from the Food and Drug Administration on Nov. 8, 2013, is a prescription medicine used with other medicines to treat partial-onset seizures. The drug is available in four table strengths: 200 mg, 400 mg, 600 mg and 800 mg; it can be taken whole or crushed, with food or without.

  • HDMA in testimony to Congress: Government, industry should partner on combating Rx drug abuse

    ARLINGTON, Va. — Healthcare Distribution Management Association president and CEO John Gray on Monday testified before the House Energy and Commerce Subcommittee on Health at a hearing on “Improving Predictability and Transparency in DEA and FDA Regulation.” HDMA is in support of the Ensuring Patient Access and Effective Drug Enforcement Act of 2014, H.R. 4069, sponsored by Reps. Marino, R-Pa., and Blackburn, R-Tenn. 

  • Boehringer Ingelheim gets FDA nod for Pradaxa

    RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate). The drug is indicated for the treatment of deep venous thrombosis and pulmonary embolism in patients who have received a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated, the company said.

  • Mallinckrodt to acquire Questcor for approximately $5.6 billion

    DUBLIN — Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. The transaction was unanimously approved by the boards of directors of both companies. Subject to customary closing conditions, the transaction currently is expected to be completed in the third calendar-quarter of 2014.

  • IMS opens IPO at $20 per share

    DANBURY, Conn. — IMS Health Holdings on Thursday announced the pricing of its initial public offering of 65 million shares of its common stock at a price to the public of $20 per share, including 52 million shares to be sold by IMS Health and 13 million shares to be sold by selling shareholders. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 9.75 million shares of common stock at the public offering price, less underwriting discounts and commissions.  

  • NABP advises pharmacies not to dispense combination drugs with more than 325 mg of APAP per dose

    MOUNT PROSPECT, Ill. — The National Association of Boards of Pharmacy on Wednesday recommended that pharmacies no longer dispense combination drugs containing more than 325 mg of acetaminophen per dosage unit in light of recent regulatory action.  

    NABP also advises that pharmacists consult with prescribers to discuss alternative products with lower acetaminophen doses.

  • Study: One-third of initial prescriptions never filled

    PHILADELPHIA — Medication nonadherence is common, but it may be reduced by lower drug costs and co-payments, as well as increased follow-up care, according to a study published earlier this week in the Annals of Internal Medicine

    Primary nonadherence was defined as not filling an initial prescription within nine months. 

  • Publix to promote Lock Your Meds campaign across Florida

    MIAMI — In an effort to prevent prescription drug abuse, and in collaboration with Informed Families/The Florida Family Partnership, all 622 Publix pharmacy stores in Florida are promoting the Lock Your Meds campaign in April 2014, the supermarket chain announced Tuesday. 

X
This ad will auto-close in 10 seconds